Since its invention in 1977, propofol has become the most frequently used i.v. anaesthetic, gaining rapid acceptance for use in sedation and general anaesthesia. Propofol is also known to produce substantial vasodilatation and bronchodilatation. 1 Indeed, propofol-induced bronchodilatation has been demonstrated in both healthy and asthmatic patients. 2 3 In spite of this clinical evidence, the cellular mechanisms by which propofol produces bronchodilatation are still under investigation. 4 7 9 Force regulation involves myosin light chain (MLC) and Ca 2+ sensitization via the RhoA/Rho kinase pathway. 10 11 Thus, there are several potential targets for propofol-induced bronchodilatation. In this regard, propofol has been found to attenuate vagal and methacholine-induced bronchoconstriction, with possible direct actions on muscarinic receptors. 12 13 Propofol also decreases ovalbumin-induced contraction of sensitized rat trachea through inhibition of serotonin. 14 Whether propofol directly affects ASM has been examined only in a few studies (albeit in varied species). Propofol has been shown to decrease peak [Ca 2+ ] i response to agonists, 15 perhaps through SR Ca 2+ release via inositol trisphosphate (IP 3 ) receptor channels, 16 but does not appear to affect Ca 2+ sensitivity. 17 On the other hand, one study suggested that all of the effects of propofol on the airway may be neurally mediated. 12 Thus, the mechanisms underlying propofolinduced bronchodilatation remain unclear.
A particular feature of propofol (and indeed its preparation) is its highly lipid nature. There is now increasing evidence that the plasma membrane of almost all cell types (including ASM) contain specialized lipid rafts, including 50-100 nm invaginations called caveolae, 18 -24 likened to be more intricate T-tubules of the striated muscle. Caveolae can facilitate interactions between plasma membrane-regulatory elements and intracellular signalling cascades. 18 -26 26 27 Previous studies have shown that local and volatile anaesthetics act via interaction with lipid rafts. 28 29 There is also evidence that caveolae specifically are involved in the actions of general anaesthetics. 30 31 However, the role of caveolae in mediating the effects of propofol is not known. Given the lipid nature of propofol, we hypothesized that the bronchodilatory effects of this anaesthetic may be mediated (at least in part) by alterations in caveolar signalling. Accordingly, in the present study, we used human ASM cells to examine the potential role of caveolae and caveolin-1 in propofol-induced bronchodilatation.
Methods

Human ASM cell preparation
The techniques for isolation of human ASM cells have been described previously. 27 Briefly, bronchi were obtained from lung tissues incidental to patient procedures in thoracic surgery at Mayo Clinic Rochester (de-identified tissues typically from lobectomies and pneumenectomies; approved by the Mayo Institutional Review Board and not considered Human Subjects Research). Tissues were initially placed in Hank's' balanced salt solution (HBSS, Invitrogen, Carlsbad, CA, USA) with 2.5 mM extracellular Ca 2+ . ASM layers were isolated and enzymatically dissociated as described previously. 32 Cells were plated in sterile culture flasks and grown in a 95% air/5% CO 2 humidified incubator using DMEM F/12 supplemented with 10% fetal bovine serum (FBS). All experiments were performed in cells before the third passage to ensure cell phenotype as verified by immunostaining for smooth muscle actin and myosin and by expression of receptors for commonly used bronchoconstrictor agonists, such as the M3 muscarinic receptor and the H1 histaminergic receptor.
Preparation of caveolar membranes
Caveolin-rich membranes were prepared as described previously. 27 Briefly, ASM strips were homogenized in cold buffer A (0.25 M sucrose, 1 mM EDTA, and 20 mM Tricine, pH 7.8) until fine emulsion was achieved. The homogenates were sonicated for 10 s each, centrifuged (1000g, 10 min, 48C), the supernatant removed and brought to 5 ml, which was layered onto 30% Percoll, and re-centrifuged (84 000g, 30 min). The plasma membrane fraction was collected and brought to 2 ml with buffer A. A crude membrane fraction was then sonicated, resuspended in OptiPrep, and then placed in a centrifuge tube. A linear 20-10% OptiPrep gradient was layered on top before centrifugation at 52 000g for 90 min. The upper membrane layer containing the caveolae was then collected for analysis. The lower membrane layer was collected as a control.
Measurement of propofol within caveolar membranes by gas chromatography
Propofol was measured within caveolar membrane fractions to confirm the connection between lipid-rich caveolae and propofol. Propofol concentrations were measured by gas chromatography -mass spectrometry (GC/MS) using a modified method as described previously. 33 34 Briefly, caveolar fractions contained in 0.5 ml sucrose buffer were mixed with 100 ml n-heptane for propofol extraction and the organic phase placed in 200 ml autosampler vials for analysis. GC/MS analysis was performed using a Waters Quattro Micro triple quadruple GC/MS/MS system (Waters, Manchester, UK) operating under electron impact ionization conditions. The column used was a DB-5MS fused silica capillary column (30 m×0.25 mm inside diameter, 0.25 mm film thickness, Agilent Technologies, USA). A temperature programme ramp was performed from 60 to 3008C at 208C min 21 . The injection temperature was set at 2508C and the transfer line temperature at 2508C. Helium was used as a carrier gas at a flow rate of 1.0 ml min 21 , and 1 ml of the sample extract was injected. 
Caveolin-1 small interference RNA
The technique for suppression of caveolin-1 expression in human ASM using small interference RNA (siRNA) caveolin-1 was recently described. 27 Briefly, siRNA duplex corresponding to bovine caveolin-1 mRNA targeting against the open reading frame, 223 -241 bases, and a negative control siRNA were selected for caveolin-1 knockdown (Dharmacon, Lafayette, CO, USA). ASM cells at 60% confluence were transfected using 50 nM siRNA and Lipofectamine 2000 (Invitrogen) in DMEM F/12 without FBS. Fresh growth medium was added 6 h after transfection and experiments performed after 48 h. Both Lipofectamine only (vehicle) and scrambled siRNA sequences were used as controls.
Western blot analysis
Proteins were separated by SDS -PAGE using the Criterion Gel System (Bio-Rad, Hercules, CA, USA) and 15% or 4-15% gradient gels. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad) for 60 min and then blocked for 1 h with 5% milk in Tris-buffered saline containing 0.1% Tween (TBST). Membranes were then incubated with anti-caveolin-1 (1:1000), anti-ERK (1:1000), anti-pERK (1:100), anti-PI3K (1:1000), or anti-RhoA (1:1000) antibodies overnight at 48C. Following three washes with TBST, primary antibodies were detected with horseradish peroxidaseconjugated secondary antibodies and signals developed by Supersignal West Pico Chemiluminescent Substrate (Pierce Chemical Co., Rockford, IL, USA).
Materials
Methyl-b-cyclodextrin (CD), Optiprep, and other chemicals were obtained from Sigma (St Louis, MO, USA) unless mentioned otherwise. All tissue culture reagents were obtained from Invitrogen. Primary and secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Propofol DMSO formulation was obtained from Sigma; propofol emulsion was obtained from the Mayo Clinic Pharmacy.
Statistics
Propofol effects on [Ca 2+ ] i responses in human ASM cells were compared with controls using Student's paired t-tests. At least 10 cells from three ASM isolations (three different patients) were compared. GC measurements were performed in samples from three patients. Values are means (SD) and n is the number of patients. Statistical significance was established at P,0.05.
Results
Propofol concentration within caveolae
To confirm our hypothesis that propofol induces bronchodilatation via interaction with caveolae, we directly measured propofol concentrations within caveolar membranes using GC. Compared with vehicle control, exposure of ASM to 10 and 30 mM resulted in significantly higher propofol concentrations within caveolar membranes (P,0.05; Fig. 1 ). Fig. 4A ). The effects of 10 vs 30 mM propofol were the same.
Effect of propofol on IP 3 receptor channels
We have previously demonstrated that SR Ca 2+ release in ASM involves both IP 3 receptor and ryanodine receptor (RyR) channels. 35 In one set of experiments, IP 3 receptor channels were first blocked with 20 mM Xestospongin C 
Effect of propofol on RyR channels
We previously demonstrated that RyR channels are blocked by high concentrations of ryanodine. 35 In this set of experiments, RyR channels were first blocked with 20 mM ryanodine for 15 min. Cells were stimulated with 10 mM histamine, thoroughly washed, treated with 30 mM propofol for 5 min, and re-stimulated with 10 mM histamine. (Fig. 4B) .
To further investigate the effects of propofol on SR Ca 2+ release via RyR channels, ASM cells were exposed to 5 mM caffeine in the absence or presence of 30 mM propofol. Thirty micromoles of propofol blunted caffeine-induced SR Ca 2+ release ( Fig. 5 ; P,0.05).
Effect of propofol on SOCE
We have previously demonstrated SOCE in ASM. 4 rapidly re-introduced to trigger SOCE. Cells were then washed thoroughly to refill SR stores, and the protocol repeated with additional exposure to 30 mM propofol 5 min before re-introduction of extracellular Ca 2+ (thus avoiding any effect of propofol on the SR release aspect). Exposure to propofol resulted in decreased SOCE in the propofol/ DMSO formulation (P,0.05; Fig. 6 ), while the propofol emulsion showed no significant changes. Since we postulated that propofol and caveolae or caveolin-1 interact, in an additional set of experiments, the experiments described above were repeated in cells treated with caveolin-1 siRNA. SOCE in cells treated with caveolin-1 siRNA was significantly reduced (P,0.05; Fig. 6B ). The addition of propofol now did not further reduce SOCE (Fig. 6B) .
Western analyses
Given the lipid nature of propofol, we tested whether this anaesthetic decreases caveolin-1 expression, offering an explanation for the observed effects. In whole-cell ] i levels were not affected by propofol. Values are means (SD) in the summary bar graph of (B), n¼3 patients, average of 60 cells per condition. *Significant propofol effect (P,0.05).
homogenates of human ASM, treatment with either propofol DMSO or emulsion formulations did not significantly alter whole-cell caveolin-1 expression. However, in caveolar fractions enriched in caveolae, propofol decreased caveolin-1 expression (Fig. 7) . Previous studies have demonstrated that intracellular mitogen-activated protein kinases such as extracellular signal-regulated kinase (ERK) are involved in [Ca 2+ ] i regulation and the effects of inflammation. 36 Other studies have shown that caveolin-1 can regulate ERK in smooth muscle. 37 -40 Accordingly, we examined whether ERK expression and phosphorylation are altered by propofol. Total ERK expression was unchanged after propofol treatment of only 5 min. However, the phosphorylated form of ERK (pERK) was significantly lower with propofol treatment Values are mean (SD) in the summary bar graphs of (B), n¼3 patients, average of 60 cells per condition; *significant propofol effect; # significant inhibitor effect (P,0.05). (Fig. 7) . Additionally, there is some evidence that the PI3K/ Akt pathway can indirectly affect ASM [Ca 2+ ] i and force regulation. Caveolin-1 is thought to activate PI3K. Accordingly, we tested whether this pathway is affected by propofol effects. However, the expression of PI3K was unchanged with propofol treatment, regardless of formulation (Fig. 7) . Furthermore, Ca 2+ sensitization during force production involves the RhoA/ rho kinase pathway. RhoA expression was decreased with propofol treatment with propofol 30 mM concentrations ( Fig. 7 ; P,0.05).
Discussion
Propofol is well known to produce bronchodilatation in different species. 17 caveolin-1) also appear to be important in the regulation of SOCE in ASM. These previous data highlight the importance of caveolae and caveolin- by Rho-kinase inhibits MLC phosphatase, thus maintaining MLC phosphorylation and promoting contraction. Rho-kinase inhibitors can attenuate the contraction of ASM in rats, which is further attenuated by the addition of propofol. 50 The relevance of the RhoA/Rho-kinase pathway to the present study lies in the fact that caveolins are thought to be essential for the activation of this pathway, 51 and caveolin effects on this pathway could modulate force in ASM. In a previous study using porcine ASM, we found that Ca 2+ sensitivity via RhoA/ Rho-kinase is indeed altered by CD. responses to histamine in human ASM cells in vitro, that is, without the confounding effect on airway neurones, underlines a direct effect on ASM itself. In this regard, the relative lack of propofol effects under conditions of suppressed caveolin-1 expression would suggest that propofol effects on the ASM are mediated (potentially in a major way) through lipid rafts. Given our previous data showing the expression of histaminergic and other receptors within caveolae of human ASM, these present data would suggest that the depletion of plasma membrane caveolae may lead to altered receptor expression or potentially disruption of caveolar interactions with intracellular structures such as the SR. In this regard, our finding that propofol effects involve RyR channels, but less so IP 3 receptor channels, is interesting. One previous study suggested that propofol affects SR Ca 2+ release via IP 3 receptor channels. 54 However, effects on RyR channels in ASM have not been reported previously. Again, given our previous finding of caveolar interactions with SR Ca 2+ regulation, 27 perhaps some of these effects are mediated by disruption of such interactions. Further studies (potentially using real-time imaging of caveolin-1) will address this issue. We have previously demonstrated that caveolae in ASM express multiple TRPC isoforms (putative SOCE channels). 4 Accordingly, we expected propofol to decrease SOCE, and indeed, we found this to be the case. The mechanisms underlying this effect are not clear, but likely involve caveolae (based on the effect of caveolin-1 siRNA). On the one hand, propofol may simply alter the extent of influx by inhibiting caveolar regulation of SOCE. We have also previously demonstrated that TRPC3 channels are expressed within caveolae. 27 Alternatively, propofol may inhibit non-caveolar TRPC isoforms. Finally, if propofol affects SR function (as evidenced by the XeC and ryanodine experiments), it may also modulate regulatory proteins such as STIM1 that are critical to SOCE. 55 -57 protein expression, caveolae and caveolin-1 may regulate intracellular signalling pathways. In human ASM, the disruption of caveolae using CD or caveolin-1 siRNA causes p42/p44 MAPK (ERK) activation and increased cell proliferation. 37 However, studies in other cell types suggest that caveolin-1 actually activates the ERK pathway, 38 -40 which is consistent with our data of propofol effects on ERK. While ERK phosphorylation may be involved, propofol effects do not appear to involve the PI3/Akt pathway, although there are some data that caveolins can interact with this signalling pathway. 58 -60 Accordingly, the activation or inhibition of specific signalling pathways after propofol exposure is likely to be complex and needs further investigation. Overall, the results of the present study suggest that propofol-induced reduction in [Ca 2+ ] i of ASM (and resultant bronchodilatation) involve the disruption of caveolae and caveolin-1 regulation of both plasma membrane and intracellular Ca 2+ regulatory mechanisms. Furthermore, propofol could interfere with signalling intermediates that are typically activated by bronchoconstrictors. While further research is needed to examine the molecular mechanisms of action for propofol, an important consideration is that given caveolar expression of muscarinic 27 and purinergic receptors, 61 caveolae could be important in different targets of propofol in producing bronchodilatation. Furthermore, given the ubiquitous expression of caveolae across cell types, the role of caveolae or caveolin-1 in mediating propofol effects in other smooth muscle types is also warranted. Finally, caveolae may be a common factor in anaesthetic action. For example, previous studies have shown that local anaesthetics and volatile anaesthetics can act via interaction with lipid rafts 28 29 and that caveolae are involved in actions of general anaesthetics. 30 31
Methodological issues
One potential concern regarding whether propofol has effects on any cell type is the formulation of propofol used. In older studies, metabisulphite, the preservative used in propofol, had also been shown to have bronchodilatory properties. For example, metabisulphite decreases methacholine-induced bronchoconstriction. 12 With the newer propofol formulation, these effects are unlikely. On the other hand, the lipid emulsion may potentially have effects on lipid rafts. However, since our data demonstrate that there is no significant difference in effect between the propofol emulsion and DMSO, this should not be an issue.
Declaration of interest
None declared.
Funding
